unpopular opinion: most of what gets said here about MASH is guesswork
unpopular opinion: most of what gets said here about MASH is guesswork. It is the sort of thing everyone half-believes and nobody writes down. Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer. Bought small because the evidence base is early. That is the…
The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.
the titration in the trials was slow and deliberate
read the histology endpoint definitions before quoting a response rate
Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.
Assumed the weight numbers were the point and was corrected.
This is the framing the board needs. It is a hepatic programme first.
Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.
Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.
phase 2 in liver disease is a different evidence question from weight